Defiance ETFs has launched the Defiance Autism Impact ETF, the first exchange-traded fund focused on companies developing autism-related products and services [1].

The fund allows investors to target a specific niche of healthcare innovation while providing a mechanism to generate funding for charities that support individuals with autism, and their families [1, 2].

Listed on the NYSE Arca under the ticker symbol ASD [1, 3], the fund targets companies creating therapies, technologies, and services for the autism community [1, 3]. The asset-management firm announced the launch on June 13, 2024 [1, 3].

As part of the fund's mission, Defiance ETFs has committed to donating a portion of its profits to autism-related charities [1]. Some reports specify that the firm will donate initial advisory profits to these causes [2].

"We believe investors want to align their portfolios with causes they care about, and this fund allows them to do that while supporting the autism community," Sylvia Jablonski, CIO and Co-Founder of Defiance ETFs, said [1].

This thematic approach to investing seeks to bridge the gap between financial markets and public health needs. By concentrating capital on companies specializing in autism, the fund aims to incentivize the development of new medical, and behavioral tools.

"This is the first ETF of its kind, and we hope it makes a meaningful impact for both investors and the autism community," a Defiance ETFs representative said [3].

“This is the first ETF of its kind, and we hope it makes a meaningful impact.”

The creation of the ASD ticker fund signals a shift toward highly specialized 'impact investing' within the science and healthcare sectors. By tying fund profits to charitable donations and focusing on a specific neurodevelopmental condition, Defiance ETFs is testing whether investors will prioritize social outcomes alongside traditional financial returns in the biotech and service markets.